Press Releases
Global Alzheimer’s Platform Foundation Announces Collaboration with Niki BioSolutions to Add APOE Genotyping to the Bio-Hermes-002 Study
Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias Washington D.C., Oct. 14, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Niki BioSolutions, Inc. (NASDAQ: NIKI) and its wholly owned subsidiary, DiamiR Biosciences Corp. (DiamiR), to the Bio-Hermes-002 study. Bio-Hermes-002 is a unique […]
Axiom Brain Health Welcomes Next Research Leader and Celebrates a Legacy of Neurological Research and Innovation
Axiom Brain Health (Axiom) a Global Alzheimer’s Platform Foundation ® (GAP) owned and operated site, is celebrating the next chapter in neurodegenerative research as Dr. Jeffrey Greenberg joins the team as Medical Director and Principal Investigator. This new leadership will drive continued momentum in the fight against Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, dementia with Lewy bodies and other […]
Global Alzheimer’s Platform Foundation Names New Medical Director at Tampa Research Site
The Global Alzheimer’s Platform Foundation® (GAP), announced today that Dr. Jeffery Greenberg is joining GAP as the Medical Director and Principal Investigator of Axiom Brain Health (Axiom), GAP’s clinical research site in Tampa, FL. Dr. Greenberg succeeds Dr. Susan Steen, Axiom’s longtime Medical Director and a Tampa Practitioner, who will retire at the end of the year. […]
GAP Statement on FDA clearance for Elecsys® pTau217
We applaud the FDA’s clearance for Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test another important milestone that has the potential to advance the Alzheimer’s diagnostic process and bring more accessible, scalable tools to physicians and specialists, ultimately benefitting people living with Alzheimer’s disease. Developed as a collaboration between Eli Lilly & Co and Roche, Elecsys® […]
Bio-Hermes-002 Completes Enrollment Marking Milestone for Innovative Alzheimer’s Study Advancing Early Detection
The Global Alzheimer’s Platform Foundation enrolled 1,000+ participants with unprecedented 27% from traditionally understudied populations Washington D.C., August 11, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) has reached full enrollment for the innovative Bio-Hermes-002 Study, successfully recruiting more than 1,000 participants. The milestone marks an important step toward advancing the next generation of blood and digital biomarker […]
Statement on the Cancellation of NIH Alzheimer’s Research Grants
The cancellation of ongoing NIH-funded Alzheimer’s research grants is a serious setback in the fight against Alzheimer’s disease. Halting peer-reviewed studies wastes taxpayer investments, disrupts years of scientific progress, and delays the discoveries that millions of patients and families urgently need. Alzheimer’s disease is one of our nation’s greatest public health challenges. Progress depends on […]
Breaking Barriers: New Findings on Biomarkers and Expanding Participation in Alzheimer’s Research
GAP Experts Share Poster Presentations at Alzheimer’s Association International Conference (AAIC) Washington D.C., July 9, 2026- The Global Alzheimer’s Platform Foundation®, (GAP) will have two poster presentations at the 2026 Alzheimer’s Association International Conference (AAIC) being held in Londong July 12 through July 15. All posters are in the Exhibit Hall in Excel London, Royal Victoria Dock, 1 […]
Global Alzheimer’s Platform Foundation Announces Strategic Partnership with Taudia for the Transformative Bio-Hermes-002 Study
Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias Washington D.C., July 8, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Taudia to the Bio-Hermes-002 study, a unique observational platform study, which evaluates blood-based and digital biomarkers across a wide spectrum of […]
GAP Applauds the Decision by Elevance Health to Explicitly Endorse the Use of Blood-Based Biomarker Testing
Washington D.C., July 1, 2026- Elevance Health, formerly Anthem Inc., updated their medical policy, to allow for blood-based biomarker testing for the detection and diagnosis of Alzheimer’s disease, making Elevance Health one of the first major payors to outline coverage criteria. GAP President John Dwyer said, “GAP applauds the decision by Elevance Health to explicitly endorse […]
Free Brain Health Assessments Available During June
Free Memory Screenings Offered Across the Country during Alzheimer’s and Brain Awareness Month WASHINGTON, DC (June 4, 2026)- Alzheimer’s research sites across the country are recognizing Alzheimer’s and Brain Awareness Month by offering free memory screenings for adults age 55 and older. Throughout June, researchers are raising awareness about brain health and the importance of learning about […]